Companies › Intra-Cellular Therapies
2 active drug programs in 17 registered trials: 9 Phase 3, 5 Phase 2, 3 Phase 4; Psychiatry, Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JNJ-99245354 (ITI-1284) 5-HT1A partial agonist | – | Phase 3 | Generalized Anxiety Disorder; Agitation Associated With Alzheimer's Dementia; Psychotic Disorders | Mar 2027 |
| Lumateperone Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor | HTR2A, DRD2, SLC6A4 | Phase 3 | Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia … | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06174116 | Lumateperone | Phase 4 | Schizophrenia | Psychiatry | Dec 2026 |
| NCT06482554 | Lumateperone | Phase 3 | Apathy | Psychiatry | Dec 2026 |
| NCT06480383 | JNJ-99245354 (ITI-1284) | Phase 2 | Generalized Anxiety Disorder | Psychiatry | Mar 2027 |
| NCT05850689 | Lumateperone | Phase 3 | Major Depressive Disorder | Psychiatry | Apr 2027 |
| NCT06690398 | Lumateperone | Phase 3 | Irritability Associated With Autism Spectrum Disorder | Psychiatry | Jun 2027 |
| NCT06706674 | Lumateperone | Phase 3 | Irritability Associated With Autism Spectrum Disorder | Psychiatry | Jun 2027 |
| NCT07734103 | Lumateperone | Phase 2 | Stuttering, Adult | Psychiatry | Jul 2027 |
| NCT06701903 | JNJ-99245354 (ITI-1284) | Phase 2 | Generalized Anxiety Disorder | Psychiatry | Oct 2027 |
| NCT06651567 | JNJ-99245354 (ITI-1284) | Phase 2 | Agitation Associated With Alzheimer's Dementia | Neurology | Dec 2027 |
| NCT07699445 | Lumateperone | Phase 4 | Bipolar Depression Depressed Phase | Psychiatry | Jan 2028 |
| NCT07799493 | Lumateperone | Phase 4 | Social Anxiety Disorder (SAD) | Psychiatry | May 2028 |
| NCT07623135 | Lumateperone | Phase 3 | Treatment Resistant Depression (TRD) | Psychiatry | Jun 2028 |
| NCT06540833 | JNJ-99245354 (ITI-1284) | Phase 2 | Psychotic Disorders | Neurology | Sep 2028 |
| NCT07807865 | JNJ-99245354 (ITI-1284) | Phase 3 | Generalized Anxiety Disorder | Psychiatry | Feb 2030 |
| NCT07856420 | JNJ-99245354 (ITI-1284) | Phase 3 | Generalized Anxiety Disorder | Psychiatry | Sep 2030 |
| NCT06372964 | Lumateperone | Phase 3 | Bipolar Depression | Psychiatry | Oct 2031 |
| NCT06229210 | Lumateperone | Phase 3 | Schizophrenia | Psychiatry | Apr 2032 |
Cybin IRL Gedeon Richter Definium Therapeutics US LB Pharmaceuticals Sichuan Jishengtang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.